Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 4/20 | 0.46 |
| ▸ | CCND1 | P24385 | 4/20 | 0.46 |
| ▸ | ALB | P02768 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 4/20 | 0.43 |
| ▸ | HTR2A | P28223 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9586206 | 0.96 | CDK4 (0.47) | HSD17B10HPGDUSP2ALDH1A1KDM4E | |
| SCHEMBL7428957 | 0.95 | HSD17B10 (0.50) | HSD17B10HPGDUSP2ALDH1A1KDM4E | |
| SCHEMBL7434089 | 0.93 | BCHE (0.45) | HSD17B10KDM4ECYP1A2LMNACDK4 | |
| SCHEMBL9585508 | 0.91 | CDK4 (0.48) | HSD17B10HPGDUSP2ALDH1A1KDM4E | |
| SCHEMBL9587246 | 0.86 | HSD17B10 (0.50) | HSD17B10HPGDUSP2ALDH1A1KDM4E | |
| SCHEMBL7424620 | 0.86 | CDK4 (0.45) | HSD17B10HPGDUSP2ALDH1A1KDM4E | |
| SCHEMBL7326732 | 0.81 | HSD17B10 (0.52) | HSD17B10HPGDUSP2ALDH1A1KDM4E | |
| SCHEMBL5421535 | 0.81 | HSD17B10 (0.52) | HSD17B10HPGDUSP2ALDH1A1KDM4E | |
| SCHEMBL7435546 | 0.73 | KMT2A (0.46) | HSD17B10HPGDUSP2ALDH1A1KDM4E | |
| SCHEMBL5420638 | 0.73 | HTR2C (0.65) | HSD17B10HPGDUSP2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7081455-B2 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-25 | — | — | US | disclosed |
| US-20040209864-A1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-10-21 | — | — | US | disclosed |
| EP-1189905-B1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20040127482-A1 | Administering substituted heterocycle fused gamma-carboline compounds for therapy of addictive behavior associated with 5HT2C receptor modulation | ROBICHAUD ALBERT J (US) | 2004-07-01 | — | — | US | disclosed |
| US-6548493-B1 | Serotonin receptor modulators (5-HT2C and 5-HT2A); treating obesity, anxiety, depression, psychological disorders, migraine, sexual disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-15 | — | — | US | disclosed |
| US-5223625-A | Antagonistic acitivity on 5-hydroxytryptamine receptors | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1993-06-29 | — | — | US | disclosed |
| EP-0377238-A1 | New annelated indolo (3,2-c)-lactams | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1990-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209864-A1 | Substituted heterocycle fused gamma-carbolines | HCRTR1, HTR2C, OPRK1 | HSD17B10 1130/4885HPGD 2720/4885USP2 3658/4885 |
| US-20040127482-A1 | Administering substituted heterocycle fused gamma-carboline compounds for therapy of addictive behavior associated with 5HT2C receptor modulation | HTR2C, HTR2B, HTR3B | HSD17B10 1738/4885HPGD 3652/4885USP2 2743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.